The DOI matches its Crossref record; 132 of the 132 references it cites were found in a registry or an index.
Tertiary lymphoid structures, drivers of the anti‐tumor responses in human cancers
Abstract
Summary: The characterization of the microenvironment of human tumors led to the description of tertiary lymphoid structures (TLS) characterized by mature dendritic cells in a T‐cell zone adjacent to B‐cell follicle including a germinal center.TLS represent sites of lymphoid neogenesis that develop in most solid cancers. Analysis of the current literature shows that the TLS presence is associated with a favorable clinical outcome for cancer patients, regardless of the approach used to quantify TLS and the stage of the disease. Using several approaches that combine immunohistochemistry, gene expression assays, and flow cytometry on large series of lung tumors, our work demonstrated that TLS are important sites for the initiation and/or maintenance of the local and systemic T‐ and B‐cell responses against tumors. Surrounded by high endothelial venules, they represent a privileged area for the recruitment of lymphocytes into tumors and generation of central‐memory T and B cells that circulate and limit cancer progression.TLS can be considered as a novel biomarker to stratify the overall survival risk of untreated cancer patients and as a marker of efficient immunotherapies. The induction and manipulation of cancer‐associated TLS using drug agonists and/or biotherapies should open new avenues to treat cancer patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Self-citationInvolvement of chemokine receptors in breast cancer metastasis
Müller, A., Homey, B., Soto, H., Ge, N., Catron, D., Buchanan, M. E., McClanahan, T., Murphy, E., Yuan, W., Wagner, S. N., et al. (2001) · Nature · doi:10.1038/35065016 · Cited by 5,340
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981
Self-citationSpatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human Cancer
Bindea, G., Mlecnik, B., Tosolini, M., Kirilovsky, A., Waldner, M., Obenauf, A. C., Angell, H., Fredriksen, T., Lafontaine, L., Berger, A., et al. (2013) · Immunity · doi:10.1016/j.immuni.2013.10.003 · Cited by 4,422
Self-citationCancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer
Pagès, F., Berger, A., Camus, M., Sanchez-Cabo, F., Costes, A., Molidor, R., Mlecnik, B., Kirilovsky, A., Nilsson, M., Damotte, D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051424 · Cited by 2,135 · cited 1×
“Thus, high densities of CD8 T cells and CD45RO memory T cells correlate with a favorable prognosis, when located at both the IM and CT (2, 3).”
BackgroundSelf-citationCancer immunotherapy via dendritic cells
Palucka, K., & Banchereau, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3258 · Cited by 2,049
RANK is essential for osteoclast and lymph node development.
Dougall, W. C., Glaccum, M., Charrier, K., Rohrbach, K., Brasel, K., De Smedt, T., Daro, E., Smith, J., Tometsko, M. E., Maliszewski, C. R., et al. (1999) · Genes & Development · doi:10.1101/gad.13.18.2412 · Cited by 1,478
Dangers of Using "Optimal" Cutpoints in the Evaluation of Prognostic Factors
Altman, D. G., Lausen, B., Sauerbrei, W., & Schumacher, M. (1994) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/86.11.829 · Cited by 1,143
Cited by
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Self-citationTertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
CD8+ T cell states in human cancer: insights from single-cell analysis
van der Leun, A. M., Thommen, D. S., & Schumacher, T. N. (2020) · Nature Reviews Cancer · doi:10.1038/s41568-019-0235-4 · Cited by 1,472
Tertiary lymphoid structures in cancer
Schumacher, T. N., & Thommen, D. S. (2022) · Science · doi:10.1126/science.abf9419 · Cited by 1,142
Schürch, C. M., Bhate, S. S., Barlow, G. L., Phillips, D. J., Noti, L., Zlobec, I., Chu, P., Black, S., Demeter, J., McIlwain, D. R., et al. (2020) · Cell · doi:10.1016/j.cell.2020.07.005 · Cited by 1,064
Dendritic Cells and Cancer Immunity
Gardner, A., & Ruffell, B. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.09.006 · Cited by 907
Tumor-infiltrating lymphocytes in the immunotherapy era
Paijens, S. T., Vledder, A., de Bruyn, M., & Nijman, H. W. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-020-00565-9 · Cited by 880
Revisiting the role of CD4+ T cells in cancer immunotherapy—new insights into old paradigms
Tay, R. E., Richardson, E. K., & Toh, H. C. (2021) · Cancer Gene Therapy · doi:10.1038/s41417-020-0183-x · Cited by 813
The clinical role of the TME in solid cancer
Giraldo, N. A., Sanchez-Salas, R., Peske, J. D., Vano, Y., Becht, E., Petitprez, F., Validire, P., Ingels, A., Cathelineau, X., Fridman, W. H., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-018-0327-z · Cited by 732
Self-citationImproving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Khan, K. A., & Kerbel, R. S. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.9 · Cited by 657
Cottrell, T. R., Thompson, E. D., Forde, P. M., Stein, J. E., Duffield, A. S., Anagnostou, V., Rekhtman, N., Anders, R. A., Cuda, J. D., Illei, P. B., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy218 · Cited by 592
Speiser, D. E., Chijioke, O., Schaeuble, K., & Münz, C. (2023) · Nature Cancer · doi:10.1038/s43018-023-00521-2 · Cited by 479
Siliņa, K., Soltermann, A., Attar, F. M., Casanova, R., Uckeley, Z. M., Thut, H., Wandres, M., Isajevs, S., Cheng, P., Curioni-Fontecedro, A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1987 · Cited by 448
Influence of the Tumor Microenvironment on NK Cell Function in Solid Tumors
Melaiu, O., Lucarini, V., Cifaldi, L., & Fruci, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2019.03038 · Cited by 419
Breast Cancer Metastasis: Mechanisms and Therapeutic Implications
Park, M., Kim, D., Ko, S., Kim, A., Mo, K., & Yoon, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126806 · Cited by 406
Sautès-Fridman, C., Lawand, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Dieu-Nosjean, M.-C. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00407 · Cited by 379
Self-citationInsights Gained from Single-Cell Analysis of Immune Cells in the Tumor Microenvironment
Ren, X., Zhang, L., Zhang, Y., Li, Z., Siemers, N., & Zhang, Z. (2021) · Annual Review of Immunology · doi:10.1146/annurev-immunol-110519-071134 · Cited by 370
Comprehensive analysis of spatial architecture in primary liver cancer
Wu, R., Guo, W., Qiu, X., Wang, S., Sui, C., Lian, Q., Wu, J., Shan, Y., Yang, Z., Yang, S., et al. (2021) · Science Advances · doi:10.1126/sciadv.abg3750 · Cited by 369
CXCL13-producing TFH cells link immune suppression and adaptive memory in human breast cancer
Gu-Trantien, C., Migliori, E., Buisseret, L., de Wind, A., Brohée, S., Garaud, S., Noël, G., Dang Chi, V. L., Lodewyckx, J.-N., Naveaux, C., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.91487 · Cited by 368
CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond
Kazanietz, M. G., Durando, M., & Cooke, M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00471 · Cited by 356
Metal Drugs and the Anticancer Immune Response
Englinger, B., Pirker, C., Heffeter, P., Terenzi, A., Kowol, C. R., Keppler, B. K., & Berger, W. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00396 · Cited by 355
Johansson-Percival, A., He, B., Li, Z.-J., Kjellén, A., Russell, K., Li, J., Larma, I., & Ganss, R. (2017) · Nature Immunology · doi:10.1038/ni.3836 · Cited by 331
Overacre-Delgoffe, A. E., Bumgarner, H. J., Cillo, A. R., Burr, A. H. P., Tometich, J. T., Bhattacharjee, A., Bruno, T. C., Vignali, D. A. A., & Hand, T. W. (2021) · Immunity · doi:10.1016/j.immuni.2021.11.003 · Cited by 318
Workel, H. H., Lubbers, J. M., Arnold, R., Prins, T. M., van der Vlies, P., de Lange, K., Bosse, T., van Gool, I. C., Eggink, F. A., Wouters, M. C. A., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0517 · Cited by 262
Spatially aware dimension reduction for spatial transcriptomics
Shang, L., & Zhou, X. (2022) · Nature Communications · doi:10.1038/s41467-022-34879-1 · Cited by 254
Learning from clinical trials of neoadjuvant checkpoint blockade
Versluis, J. M., Long, G. V., & Blank, C. U. (2020) · Nature Medicine · doi:10.1038/s41591-020-0829-0 · Cited by 234
Zhang, Q.-F., Li, J., Jiang, K., Wang, R., Ge, J.-L., Yang, H., Liu, S.-J., Jia, L.-T., Wang, L., & Chen, B.-L. (2020) · Theranostics · doi:10.7150/thno.44871 · Cited by 177
Zeng, Q., Yang, J., Ji, J., Wang, P., Zhang, L., Yan, G., Wu, Y., Chen, Q., Liu, J., Zhang, G., et al. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2061396 · Cited by 54
Metadata
- Authors
- Dieu‐Nosjean, M., Giraldo, N. A., Kaplon, H., Germain, C., Fridman, W. H., & Sautès‐Fridman, C.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2016-04-18
- Volume
- 271
- Issue
- 1
- Pages
- 260-275
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2339442385
- Cited by
- 417
- References
- 132
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.